<DOC>
	<DOCNO>NCT00516880</DOCNO>
	<brief_summary>Peritoneal dialysis patient increase risk cardiovascular morbidity mortality relate presence accelerate atherosclerosis . Our recent data show inflammation predicts mortality cardiovascular death , independent cardiovascular risk factor peritoneal dialysis patient . As considerable proportion peritoneal dialysis patient show evidence inflammation , raise important question whether anti-inflammatory treatment cardiovascular survival benefit patient . The peroxisome proliferator-activated receptor-gamma ( PPAR-g ) agonist class drug insulin sensitize property . Recent experimental clinical study demonstrate class drug anti-inflammatory anti-atherosclerotic property insulin sensitize effect type 2 diabetic . We therefore hypothesize modulation PPAR-g activity may novel therapeutic strategy reduce inflammation retard progression atherosclerosis possibly lower mortality peritoneal dialysis patient .</brief_summary>
	<brief_title>Targeting Peroxisome Proliferator-activated Receptor-gamma Peritoneal Dialysis Patients - Will Reduce Inflammation , Atherosclerosis , Calcification Improve Survival Peritoneal Dialysis Patients ?</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Both prevalent patient patient newly start continuous ambulatory peritoneal dialysis age 20 75 without diabetes mellitus consider eligible study entry . For patient newly start continuous ambulatory peritoneal dialysis , suitable recruitment study one month continuous ambulatory peritoneal dialysis . Patients underlying malignancy Patients chronic liver disease liver cirrhosis Patients hepatitis B C positive Patients active infection Patients chronic active inflammatory disease systemic lupus erythematosus , rheumatoid arthritis Patients refuse study participation Patients underlie congenital heart disease rheumatic heart disease Patients poor general condition Patients plan live relate kidney transplant within 2 year Female patient pregnancy Patients history recurrent hypoglycemia Patients Class III IV congestive heart failure Patients already receive glitazones treatment screen visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>